[1] Chen HJ, Pang YZ, Wu JX, et al.  Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47(8): 1820-1832.   doi: 10.1007/s00259-020-04769-z
[2]

Windisch P, Zwahlen DR, Giesel FL, et al. Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review[J/OL]. EJNMMI Res, 2021, 11(1): 18[2023-01-08]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-021-00761-2. DOI: 10.1186/s13550-021-00761-2.
[3] Ping QR, Yan RP, Cheng X, et al.  Cancer-associated fibroblasts: overview, progress, challenges, and directions[J]. Cancer Gene Ther, 2021, 28(9): 984-999.   doi: 10.1038/s41417-021-00318-4
[4] Sahai E, Astsaturov I, Cukierman E, et al.  A framework for advancing our understanding of cancer-associated fibroblasts[J]. Nat Rev Cancer, 2020, 20(3): 174-186.   doi: 10.1038/s41568-019-0238-1
[5] Yazbeck R, Jaenisch SE, Abbott CA.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein[J]. Protoplasma, 2018, 255(1): 375-386.   doi: 10.1007/s00709-017-1129-5
[6] Rettig WJ, Garin-Chesa P, Beresford HR, et al.  Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells[J]. Proc Natl Acad Sci USA, 1988, 85(9): 3110-3114.   doi: 10.1073/pnas.85.9.3110
[7] Lindner T, Loktev A, Altmann A, et al.  Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. J Nucl Med, 2018, 59(9): 1415-1422.   doi: 10.2967/jnumed.118.210443
[8] Dębiec K, Wydmański J, d'Amico A, et al.  The application of 18F-FDG-PET/CT in gastric cancerstaging and factors affecting its sensitivity[J]. Hell J Nucl Med, 2021, 24(1): 66-74.   doi: 10.1967/s002449912308
[9] Qin CX, Song YMH, Gai YK, et al.  Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management[J]. Eur J Nucl Med Mol Imaging, 2022, 49(12): 4228-4240.   doi: 10.1007/s00259-022-05847-0
[10] Kuten J, Levine C, Shamni O, et al.  Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49(2): 743-750.   doi: 10.1007/s00259-021-05494-x
[11] Kömek H, Can C, Kaplan İ, et al.  Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(11): 3898-3909.   doi: 10.1007/s00259-022-05839-0
[12] Koerber SA, Staudinger F, Kratochwil C, et al.  The role of 68Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience[J]. J Nucl Med, 2020, 61(9): 1331-1336.   doi: 10.2967/jnumed.119.237016
[13] 覃春霞, 宋杨美惠, 刘芳, 等.  68Ga-FAPI PET对结直肠癌再分期的诊断价值及对治疗决策的影响[J]. 中华核医学与分子影像杂志, 2021, 41(12): 717-721.   doi: 10.3760/cma.j.cn321828-20210901-00306
Qin CX, Song YMH, Liu F, et al.  Diagnostic value of 68Ga-FAPI PET for restaging and its impact on treatment decision in patients with colorectal cancer[J]. Chin J Nucl Med Mol Imaging, 2021, 41(12): 717-721.   doi: 10.3760/cma.j.cn321828-20210901-00306
[14] Marisa L, Blum Y, Taieb J, et al.  Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer[J]. Clin Cancer Res, 2021, 27(17): 4768-4780.   doi: 10.1158/1078-0432.CCR-21-0529
[15] Strating E, Wassenaar E, Verhagen M, et al.  Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging[J]. Br J Cancer, 2022, 127(1): 145-155.   doi: 10.1038/s41416-022-01748-z
[16] Guo W, Pang YZ, Yao LL, et al.  Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1604-1617.   doi: 10.1007/s00259-020-05095-0
[17] Shi XM, Xing HQ, Yang XB, et al.  Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1593-1603.   doi: 10.1007/s00259-020-05070-9
[18] Wang H, Zhu WW, Ren SH, et al.  68Ga-FAPI-04 versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 693640-.   doi: 10.3389/fonc.2021.693640
[19] Zhang ZY, Jia GR, Pan GX, et al.  Comparison of the diagnostic efficacy of 68Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2877-2888.   doi: 10.1007/s00259-022-05729-5
[20] Röhrich M, Naumann P, Giesel FL, et al.  Impact of 68Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas[J]. J Nucl Med, 2021, 62(6): 779-786.   doi: 10.2967/jnumed.120.253062
[21] Pang YZ, Zhao L, Shang QH, et al.  Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(4): 1322-1337.   doi: 10.1007/s00259-021-05576-w
[22] Kratochwil C, Flechsig P, Lindner T, et al.  68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. J Nucl Med, 2019, 60(6): 801-805.   doi: 10.2967/jnumed.119.227967
[23] Polack M, Hagenaars SC, Couwenberg A, et al.  Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT[J]. Clin Transl Oncol, 2022, 24(9): 1776-1784.   doi: 10.1007/s12094-022-02832-9
[24] Fu LL, Huang S, Wu HB, et al.  RETRACTED ARTICLE: superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer[J]. Eur Radiol, 2022, 32(9): 6281-6290.   doi: 10.1007/s00330-022-08743-1
[25] Moradi F, Iagaru A.  Will FAPI PET/CT replace FDG PET/CT in the next decade? Counterpoint–No, not so fast![J]. AJR Am J Roentgenol, 2021, 216(2): 307-308.   doi: 10.2214/AJR.20.23794
[26] Zhao L, Pang YZ, Luo ZM, et al.  Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2021, 48(6): 1944-1955.   doi: 10.1007/s00259-020-05146-6
[27] Mo SB, Cai GX.  Multidisciplinary treatment for colorectal peritoneal metastases: review of the literature[J]. Gastroenterol Res Pract, 2016, 2016: 1516259-.   doi: 10.1155/2016/1516259
[28] Alan-Selçuk N, Ergen S, Demirci E, et al.  [68Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach[J]. Eur J Nucl Med Mol Imaging, 2021, 48(13): 4523-4524.   doi: 10.1007/s00259-021-05213-6
[29] Fu LL, Hu KZ, Tang GH, et al.  [68Ga]Ga-FAPI-04 PET/CT imaging in signet-ring cell carcinoma of sigmoid colon[J]. Eur J Nucl Med Mol Imaging, 2021, 48(5): 1690-1691.   doi: 10.1007/s00259-020-05155-5
[30] Şahin E, Elboğa U, Çelen YZ, et al.  Comparison of 68Ga-DOTA-FAPI and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer[J]. Eur J Radiol, 2021, 142: 109867-.   doi: 10.1016/j.ejrad.2021.109867
[31] Pang YZ, Zhao L, Luo ZM, et al.  Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers[J]. Radiology, 2021, 298(2): 393-402.   doi: 10.1148/radiol.2020203275
[32] Gong WD, Yang X, Wu JH, et al.  68Ga-FAPI PET/CT imaging of multiple muscle metastases of pancreatic cancer[J]. Clin Nucl Med, 2022, 47(1): 73-75.   doi: 10.1097/RLU.0000000000003888
[33] Liu QF, Shi S, Xu XP, et al.  The superiority of [68Ga]-FAPI-04 over [18F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma[J]. Eur J Nucl Med Mol Imaging, 2021, 48(4): 1248-1249.   doi: 10.1007/s00259-020-04997-3
[34] Rao ZJ, Wu J, Jiang GH, et al.  Cardiac metastasis from esophageal carcinoma detected on 18F-FDG PET/CT and 68Ga-FAPI PET/CT scan[J]. J Nucl Cardiol, 2022, 29(6): 3590-3592.   doi: 10.1007/s12350-021-02645-3
[35] Ristau J, Giesel FL, Haefner MF, et al.  Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer[J]. Mol Imaging Biol, 2020, 22(6): 1495-1500.   doi: 10.1007/s11307-020-01548-y
[36] Palma DA, Olson R, Harrow S, et al.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185): 2051-2058.   doi: 10.1016/S0140-6736(18)32487-5
[37]

Liermann J, Syed M, Ben-Josef E, et al. Impact of FAPI-PET/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer[J/OL]. Cancers (Basel), 2021, 13(4): 796[2023-01-08]. https://www.mdpi.com/2072-6694/13/4/796. DOI: 10.3390/cancers13040796.
[38] Chen HJ, Zhao L, Ruan D, et al.  Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings[J]. Eur J Nucl Med Mol Imaging, 2021, 48(1): 73-86.   doi: 10.1007/s00259-020-04940-6
[39] Yang X, Huang YL, Mou CR, et al.  Chronic colitis mimicking malignancy on 68Ga-FAPI PET/CT[J]. Clin Nucl Med, 2022, 47(2): 159-160.   doi: 10.1097/RLU.0000000000003793